http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2566563-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d466be25a7bcade71087d1364c441de7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-11043 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 |
| filingDate | 2010-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c45c18d49e415b23f7d6d69c919e34e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecead5b3f8d79dcc508f9b806eb817a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de854810dea6d3b0fed084e552fab026 |
| publicationDate | 2015-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2566563-C2 |
| titleOfInvention | Aslv-based vector system |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to field of biotechnology, genetic engineering and virology. In addition to SIN-vector system contains besides first helper plasmid, intended for expression of viral fusion protein gag-pol, and second helper plasmid, intended for expression of envelope protein (env) of retrovirus. First and second helper plasmids, contained in packaging cell line or applied for its short-term transfection, serve for creation of non-replicating (RCR-incompetent) viral particles. Viral particles contain RNA, which contains on 3'-end SIN-LTR, claimed in invention, where RNA can have therapeutically effective segment, which, for instance, represents transgene. For this purpose extensive deletion of U3-region, which in the process of reverse transcription is copied in 5' LTR, is provided in 3'-SIN-LTR. In addition, all coding ASLV regions, as well as retroviral splicing donor sites are removed from SIN-vector. Invention can be applied in genetic therapy. n EFFECT: viral self-inactivating (SIN) vector, based on virus of sarcoma and avian leukaemia virus (ASLV), and cleaving-packaging system are described. n 24 cl, 15 dwg, 2 tbl, 4 ex |
| priorityDate | 2009-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 150.